GO:0046069 cGMP catabolic process: Degradation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0046069 cGMP catabolic process describes the biochemical breakdown of cyclic GMP (guanosine 3',5'-cyclic monophosphate), a key second messenger.
• The major enzymes that execute cGMP catabolism are phosphodiesterases (PDEs), especially PDE5, PDE6, PDE9, and PDE11, which hydrolyze the cyclic phosphate bond.
• cGMP catabolism is essential for terminating NO-cGMP signaling, thereby controlling vascular tone, platelet function, cardiac contractility, and neuronal signaling.
• Dysregulated cGMP degradation contributes to cardiovascular diseases, erectile dysfunction, pulmonary hypertension, and neurodegenerative conditions such as Alzheimer's disease.
• Research on cGMP catabolic process uses knockout and point-mutation cell models, phosphodiesterase inhibitors, and real-time imaging of cGMP dynamics.
• EDITGENE provides CRISPR knockout, knock-in, point-mutation, overexpression cell models and library screening to study genes involved in cGMP catabolism.
Description
Cyclic GMP (cGMP) is a ubiquitous second messenger that regulates diverse physiological processes, including smooth muscle relaxation, platelet aggregation, cardiac contractility, and neuronal plasticity. The intracellular levels of cGMP are tightly controlled by the balance between its synthesis by guanylyl cyclases and its degradation via the cGMP catabolic process (GO:0046069). This catabolic process is primarily mediated by cyclic nucleotide phosphodiesterases (PDEs), which hydrolyze the 3',5'-cyclic phosphate bond to yield the inactive linear metabolite 5'-GMP. Understanding cGMP catabolism is critical because pharmacological inhibition of PDEs is a well-established therapeutic strategy for cardiovascular and erectile disorders. Moreover, emerging evidence links altered cGMP degradation to neurodegenerative diseases and cancer, making this pathway a focal point for drug discovery and gene editing research.
cGMP catabolic process At A Glance
| GO ID | GO:0046069 |
|---|---|
| GO term | cGMP catabolic process |
| Ontology | biological_process |
| Synonym | cGMP breakdown; cGMP catabolism; cGMP degradation |
| Major function | Hydrolysis of cyclic GMP to 5'-GMP, terminating cGMP signaling |
| Key enzymes | Phosphodiesterases (PDE1, PDE2, PDE3, PDE5, PDE6, PDE9, PDE10, PDE11) |
| Subcellular location | Cytosol, plasma membrane, and specialized compartments (e.g., photoreceptor outer segments) |
| Regulatory inputs | Calcium/calmodulin, cGMP itself, phosphorylation, and protein-protein interactions |
| Associated diseases | Cardiovascular disease, erectile dysfunction, pulmonary hypertension, neurodegeneration |
What Is GO:0046069?
The cGMP catabolic process (GO:0046069) is defined as the chemical reactions and pathways that result in the breakdown of cyclic GMP, guanosine 3',5'-phosphate. This process involves the enzymatic hydrolysis of the cyclic nucleotide to 5'-GMP, thereby terminating its signaling actions. It is a key regulatory mechanism for controlling the intensity and duration of cGMP-mediated signal transduction in cells.
Why Is cGMP catabolic process Important in Cell Biology?
The cGMP catabolic process is fundamental for resetting cGMP signaling after its activation by nitric oxide (NO) or natriuretic peptides. Without efficient degradation, sustained cGMP elevation would lead to pathological vasodilation, bleeding disorders, and impaired cardiac function. Moreover, PDE-mediated cGMP breakdown is the target of widely prescribed drugs such as sildenafil and tadalafil, underscoring its clinical relevance. In the brain, cGMP catabolism influences synaptic plasticity and memory, and its dysregulation has been implicated in Alzheimer's disease. Thus, understanding the molecular players and regulatory mechanisms of cGMP degradation is essential for both basic biology and therapeutic development.
• Terminates NO-cGMP signaling to prevent excessive vasodilation and hypotension.
• Regulates platelet aggregation and thrombosis by controlling cGMP levels in platelets.
• Modulates cardiac contractility and protects against hypertrophy.
• Influences neuronal signaling, synaptic plasticity, and memory formation.
• Dysregulation is linked to erectile dysfunction, pulmonary hypertension, and heart failure.
• PDE5 inhibitors (e.g., sildenafil) act by blocking cGMP catabolism, validating the pathway as a drug target.
• Altered cGMP degradation contributes to Alzheimer's disease pathology via calcium signaling crosstalk.
• cGMP catabolism is essential for photoreceptor function and vision.
• Provides a mechanism for cross-talk with cAMP signaling through shared PDEs.
• CRISPR-based editing of PDE genes enables precise dissection of cGMP catabolic functions.
What Happens During cGMP catabolic process?
Substrate recognition and binding
In simple terms: The enzyme grabs the cGMP molecule.
Phosphodiesterases (PDEs) specifically recognize cyclic GMP through conserved catalytic domains that form a hydrophobic pocket accommodating the guanine ring. The binding is often regulated by allosteric cGMP binding to GAF domains, which enhances catalytic activity. This step ensures that only the correct cyclic nucleotide is targeted for degradation.
Catalytic hydrolysis of the cyclic phosphate bond
In simple terms: The enzyme cuts the ring, making cGMP inactive.
The catalytic mechanism involves a metal-ion-dependent hydrolysis (typically Zn2+ and Mg2+) that cleaves the 3',5'-cyclic phosphate bond, converting cGMP to 5'-GMP. This reaction is highly efficient and essentially irreversible under physiological conditions. The resulting 5'-GMP is no longer able to activate cGMP-dependent protein kinases (PKG), ion channels, or other effectors.
Product release and enzyme turnover
In simple terms: The enzyme releases the broken product and is ready to work again.
After hydrolysis, 5'-GMP is released from the active site, allowing the PDE to catalyze another round of cGMP breakdown. The turnover rate varies among PDE isoforms, contributing to distinct spatiotemporal cGMP gradients. This dynamic regulation is crucial for maintaining compartmentalized cGMP signaling.
Integration with cellular signaling networks
In simple terms: The breakdown of cGMP affects many other signals in the cell.
cGMP catabolism is tightly coupled to calcium signaling, as some PDEs (e.g., PDE1) are activated by Ca2+/calmodulin. Conversely, cGMP can modulate cAMP levels by regulating PDE2 and PDE3, creating a complex interplay between cyclic nucleotide pathways. This integration ensures that cGMP degradation is not an isolated event but a hub for signal transduction.
Key Genes Involved in GO:0046069 cGMP catabolic process
The following genes encode enzymes and regulators that directly participate in or control the cGMP catabolic process.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PDE5A | Hydrolyzes cGMP in smooth muscle and platelets | Target of sildenafil; cardiovascular and erectile function studies |
| PDE6A | Photoreceptor-specific cGMP PDE | Mutations cause retinitis pigmentosa; vision research |
| PDE6B | Photoreceptor cGMP PDE subunit | Linked to congenital stationary night blindness |
| PDE9A | High-affinity cGMP-specific PDE | Brain-enriched; memory and neurodegeneration studies |
| PDE10A | Dual-specificity PDE (cAMP/cGMP) | Expressed in striatum; schizophrenia and Huntington's models |
| PDE11A | cGMP-specific PDE | Adrenal and prostate biology; cancer research |
| PDE1A | Ca2+/calmodulin-dependent PDE | Vascular tone and cardiac hypertrophy |
| PDE1B | Ca2+/calmodulin-dependent PDE | Neuronal signaling and addiction studies |
| PDE2A | cGMP-stimulated PDE | Cross-talk with cAMP; adrenal and brain function |
| PDE3A | cGMP-inhibited PDE | Cardiac contractility and platelet aggregation |
| PDE3B | cGMP-inhibited PDE | Insulin secretion and metabolism |
| PRKG1 | cGMP-dependent protein kinase I | Major effector of cGMP; smooth muscle relaxation |
| PRKG2 | cGMP-dependent protein kinase II | Intestinal secretion and bone growth |
| CNGA1 | Cyclic nucleotide-gated channel | Phototransduction and olfactory signaling |
| CNGB1 | Cyclic nucleotide-gated channel subunit | Retinal function and cGMP feedback |
| GUCY1A3 | Guanylyl cyclase subunit | cGMP synthesis; provides substrate for catabolism |
| GUCY1B3 | Guanylyl cyclase subunit | NO-sensitive guanylyl cyclase; vascular biology |
How Is cGMP catabolic process Regulated?
The cGMP catabolic process is regulated at multiple levels. Phosphodiesterase activity can be modulated by allosteric cGMP binding to GAF domains, phosphorylation by kinases such as PKA and PKG, and interactions with scaffolding proteins. Calcium/calmodulin activates PDE1, linking cGMP degradation to intracellular calcium signals. Additionally, cGMP itself can stimulate PDE2 and inhibit PDE3, creating feedback loops that fine-tune cyclic nucleotide levels. Transcriptional regulation of PDE genes by cGMP-responsive elements has also been reported, providing long-term control of catabolic capacity.
cGMP catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PDE5A | Pulmonary hypertension, erectile dysfunction | Knockout mouse; smooth muscle cell overexpression |
| PDE6B | Retinitis pigmentosa | Point-mutation knock-in in retinal cells |
| PDE9A | Alzheimer's disease, memory deficits | Knockout and overexpression in neurons |
| PDE3A | Cardiac hypertrophy, thrombosis | Cardiomyocyte-specific knockout |
| PDE11A | Adrenal hyperplasia, prostate cancer | Knock-in of patient mutations |
Cardiovascular diseases
Impaired cGMP catabolism leads to excessive vasodilation and hypotension, while enhanced degradation contributes to hypertension and heart failure. PDE5A inhibitors are used to treat pulmonary arterial hypertension by blocking cGMP breakdown. In platelets, altered cGMP degradation affects thrombosis risk.
Neurodegenerative disorders
In Alzheimer's disease, cGMP catabolism is dysregulated, affecting calcium signaling and synaptic function. PDE9A inhibition is being explored to enhance cGMP levels and improve memory. Reduced cGMP degradation may also contribute to neuroinflammation.
Retinal degenerations
Mutations in PDE6A and PDE6B, which are essential for cGMP catabolism in photoreceptors, cause retinitis pigmentosa and congenital stationary night blindness. Loss of PDE6 activity leads to toxic cGMP accumulation and photoreceptor death.
Cancer
Altered expression of PDEs that degrade cGMP, such as PDE5A and PDE11A, has been observed in various cancers, influencing cell proliferation and apoptosis. Targeting cGMP catabolism is a potential anticancer strategy.
From cGMP catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PDE5A loss alter cGMP levels and vascular tone? | PDE5A knockout cell line (e.g., HEK293 or SMC) |
| How does a PDE6B point mutation affect photoreceptor survival? | Point-mutation knock-in in retinal progenitor cells |
| Can overexpression of PDE9A mimic Alzheimer's-related cGMP decline? | PDE9A overexpression in neuronal cell lines |
| What is the role of PDE2A in cross-talk with cAMP? | Tagged knock-in for live-cell imaging |
| Which PDE isoforms compensate for PDE5A loss? | CRISPR library screening in knockout background |
| Does a disease-associated PDE11A variant affect catalytic activity? | Knock-in of variant in adrenal cell model |
How to Study the cGMP catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| cGMP hydrolysis assay | Enzymatic conversion of cGMP to 5'-GMP | PDE activity in cell lysates |
| Live-cell cGMP imaging | Intracellular cGMP dynamics | Real-time degradation in neurons |
| CRISPR knockout screen | Genes affecting cGMP levels | Discovery of novel regulators |
| RNA-seq | Transcript levels of PDEs and effectors | Expression profiling in disease models |
| Phosphoproteomics | Phosphorylation of PDEs and regulators | Signaling crosstalk studies |
| FRET-based sensor | cGMP concentration changes | Compartmentalized signaling |
| PDE inhibitor profiling | Selectivity and potency | Drug discovery for cGMP catabolism |
Biochemical assays for cGMP hydrolysis
Radioenzymatic or fluorescent assays measure the conversion of cGMP to 5'-GMP by recombinant PDEs or cell lysates. These methods quantify catalytic activity and enable kinetic analysis of mutants.
Live-cell imaging of cGMP dynamics
Genetically encoded cGMP sensors (e.g., cGi500) allow real-time visualization of cGMP degradation in living cells. This approach reveals spatiotemporal regulation of catabolism.
CRISPR-based genetic screens
Pooled CRISPR knockout libraries can identify genes that modulate cGMP levels or PDE inhibitor sensitivity. Hits are validated by targeted editing and functional assays.
Transcriptomics and proteomics
RNA-seq and mass spectrometry quantify expression of PDEs and interacting proteins under conditions that alter cGMP catabolism. Post-translational modifications can be mapped by phosphoproteomics.
How CRISPR Can Be Used to Study GO:0046069 cGMP catabolic process
Knockout
CRISPR knockout of PDE genes (e.g., PDE5A, PDE9A) abolishes cGMP catabolism, leading to elevated cGMP and altered downstream signaling. These models are used to study the physiological consequences of loss of function and to validate drug targets.
Point Mutation
Introducing disease-associated point mutations (e.g., in PDE6B) via CRISPR base editing or HDR allows precise modeling of catalytic defects and cGMP accumulation. Such models help dissect genotype-phenotype relationships.
Knock-in
Knock-in of tagged PDEs (e.g., GFP-PDE5A) enables live-cell imaging and proteomic analysis of cGMP catabolism complexes. This approach reveals subcellular localization and interaction partners.
Overexpression
CRISPR activation or lentiviral overexpression of PDEs increases cGMP degradation, mimicking pathological states of low cGMP. These models are useful for studying diseases like Alzheimer's where cGMP signaling is impaired.
How EDITGENE Supports cGMP catabolic process Research
Researchers studying cGMP catabolic process-related genes often need to determine whether a candidate gene is causally involved in cGMP degradation, and to dissect its precise function using isogenic cell models. EDITGENE provides end-to-end CRISPR services to generate such models with high efficiency and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for cGMP catabolic process research.
Frequently Asked Questions About cGMP catabolic process
What is cGMP catabolic process?
It is the biochemical breakdown of cyclic GMP (cGMP) to 5'-GMP, primarily by phosphodiesterases, terminating cGMP signaling.
What genes are involved in cGMP catabolic process?
Key genes include PDE5A, PDE6A, PDE6B, PDE9A, PDE10A, PDE11A, and PDE1-3 isoforms, as well as regulators like PRKG1 and PRKG2.
What is the GO ID for cGMP catabolic process?
The Gene Ontology ID is GO:0046069.
How is cGMP degraded?
cGMP is hydrolyzed by phosphodiesterases to 5'-GMP, a reaction that requires metal ions and is regulated by allosteric cGMP binding and phosphorylation.
Which enzymes break down cGMP?
Cyclic nucleotide phosphodiesterases (PDEs), especially PDE5, PDE6, and PDE9, are the major enzymes that break down cGMP.
What diseases are linked to cGMP catabolism?
Cardiovascular diseases, erectile dysfunction, pulmonary hypertension, retinal degenerations, and Alzheimer's disease.
How can I study cGMP catabolic process in the lab?
Use biochemical assays, live-cell imaging with cGMP sensors, CRISPR knockout models, and phosphodiesterase inhibitors.
What are the research methods for cGMP catabolism?
Common methods include cGMP hydrolysis assays, FRET-based sensors, RNA-seq, proteomics, and CRISPR screens.
Can CRISPR be used to study cGMP catabolic process?
Yes, CRISPR knockout, knock-in, and point-mutation models enable precise dissection of PDE gene functions.
What cell models are available for cGMP catabolism research?
EDITGENE offers knockout, point-mutation, knock-in, and overexpression cell models for PDEs and related genes.
Conclusion
The cGMP catabolic process (GO:0046069) is a central regulatory node that controls the duration and intensity of cGMP signaling. Through the action of phosphodiesterases, cGMP is hydrolyzed to 5'-GMP, a reaction that is essential for cardiovascular, neuronal, and retinal physiology. Dysregulation of this process contributes to a wide range of diseases, making it a prime target for therapeutic intervention. Advances in CRISPR gene editing now allow researchers to create precise cellular models to study cGMP catabolism and identify new drug targets.
References
- 1. Sager G. 2004. Cyclic GMP transporters.. Neurochem Int 45(6):865-73 PMID: 15312981
- 2. Adler J et al.. 2020. Targets of cGMP/cGKI in Cardiac Myocytes.. J Cardiovasc Pharmacol 75(6):494-507 PMID: 32168155
- 3. Kemp-Harper B et al.. 2009. cGMP in the vasculature.. Handb Exp Pharmacol PMID: 19089340
- 4. Jehle A et al.. 2022. The Interplay between cGMP and Calcium Signaling in Alzheimer's Disease.. Int J Mol Sci 23(13) PMID: 35806059
- 5. Schlossmann J et al.. 2003. Signaling through NO and cGMP-dependent protein kinases.. Ann Med 35(1):21-7 PMID: 12693609
- 6. Smolenski A. 2012. Novel roles of cAMP/cGMP-dependent signaling in platelets.. J Thromb Haemost 10(2):167-76 PMID: 22136590
- 7. Pilz RB et al.. 2005. Role of cyclic GMP in gene regulation.. Front Biosci 10:1239-68 PMID: 15769622
- 8. Pilz RB et al.. 2003. Regulation of gene expression by cyclic GMP.. Circ Res 93(11):1034-46 PMID: 14645134
